Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q2 2024 Earnings Conference
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q2 2024 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript:
以下是Relmada Therapeutics,Inc.(RLMD) Q2 2024 業績會議錄摘要:
Financial Performance:
金融業績:
Relmada reported a decrease in R&D expenses for Q2 2024 to $10.7 million from $13.7 million in Q2 2023, attributing the decline to the completion of studies.
General and administrative expenses also decreased to $8.1 million in Q2 2024 from $12.3 million in the same period last year, mainly due to reduced stock-based compensation.
The net loss for the quarter was $17.8 million, compared to $25.3 million in Q2 2023.
Cash, cash equivalents, and short-term investments as of June 30, 2024, stood at approximately $70.4 million compared to $96.3 million as of December 31, 2023.
Relmada報告Q2 2024年的研發費用下降至1070萬美元,而Q2 2023年爲1370萬美元,將這一下降歸因於研究完成。
總和行政費用也從去年同期的1230萬美元下降至Q2 2024的810萬美元,主要是由於股票授予減少。
本季度淨虧損爲1780萬美元,而Q2 2023年爲2530萬美元。
截至2024年6月30日,現金、現金等價物和短期投資約爲7040萬美元,而截至2023年12月31日爲9630萬美元。
Business Progress:
業務進展:
Relmada is moving forward with its Phase 3 studies for REL-1017, targeting major depressive disorders, and plans to complete enrollment soon.
Announced plans to initiate a Phase 1 study for REL-P11, a psilocybin program intended for metabolic diseases, with Phase 2a to start in H1 2025.
Relmada正在推進針對重度抑鬱症的REL-1017第3期研究,並計劃很快完成招募。
宣佈計劃啓動REL-P11的第1期研究,這是一項針對代謝疾病的賽洛西賓計劃,第2a期將於2025年上半年開始。
Opportunities:
機會:
Planned completion of Phase 3 studies for REL-1017 could potentially lead to NDA submission, opening avenue to new markets if approved.
Launching a Phase 1 study for REL-P11 highlights expansion into treatment for metabolic disorders.
REL-1017第3期研究計劃的完成可能會導致新藥申請提交,如果獲得批准,將開闢新市場。
啓動REL-P11第1期研究突顯了公司擴展治療代謝性疾病的進展。
Risks:
風險:
The company acknowledged an approximately 80% screen failure rate in current studies versus 50% in prior studies, indicating potentially stringent or misaligned enrollment criteria that could delay timelines or affect study outcomes.
公司承認當前研究的篩選失敗率約爲80%,而先前的研究爲50%,表明可能存在嚴格或不合適的招募標準,這可能會延遲時間表或影響研究結果。
More details: Relmada Therapeutics IR
更多詳情:Relmada Therapeutics IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。